Fortress Biotech Inc
FBIOP
Company Profile
Business description
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Contact
1111 Kane Concourse
Suite 301
Bay Harbor IslandFL33154
USAT: +1 781 652-4500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
101
Stocks News & Analysis
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks
What now for Santos after takeover offer collapses?
Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks
Morningstar initiates coverage on small cap ASX REIT
Coverage of ASX listed REIT as investor interest in property continues to grow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,061.20 | 61.30 | -0.67% |
CAC 40 | 7,929.31 | 74.70 | 0.95% |
DAX 40 | 23,778.97 | 104.44 | 0.44% |
Dow JONES (US) | 46,142.42 | 124.10 | 0.27% |
FTSE 100 | 9,236.55 | 8.44 | 0.09% |
HKSE | 26,545.10 | 106.59 | 0.40% |
NASDAQ | 22,470.72 | 209.40 | 0.94% |
Nikkei 225 | 45,045.81 | 143.54 | 0.32% |
NZX 50 Index | 13,231.66 | 3.23 | -0.02% |
S&P 500 | 6,631.96 | 31.61 | 0.48% |
S&P/ASX 200 | 8,773.50 | 75.00 | -0.85% |
SSE Composite Index | 3,820.09 | 11.57 | -0.30% |